Alnylam reports positive results from phase 3 study of lumasiran for the treatment of primary hyperoxaluria

Alnylam reports positive topline results from illuminate-b phase 3 study of lumasiran for the treatment of primary hyperoxaluria type 1 in children under the age of six.alnylam - lumasiran demonstrated clinically significant reduction in urinary oxalate levels in children as young as four months old.alnylam pharmaceuticals - study safety & tolerability profile consistent with that observed in illuminate-a phase 3 pivotal study.
ALNY Ratings Summary
ALNY Quant Ranking